Latest results from the makers of Revita, the revolutionary ‘intestine resurfacing’ device being proposed as a treatment for T2D, offer a glimmer of light in the relentless quest to find a way of tackling the root cause of the condition.
Fractyl Health the manufacturers of Revita have announced the results from a study of 34 people in Europe and South America who had the procedure up two years ago. The study showed there was an average one per cent fall from 8.5% to 7.5% in HbAc1 – the level of red blood cell proteins linked to sugar which is the standard method of measuring diabetes. Volunteers in the trial also experienced an average 3.1kg (6.8lbs) weight loss, and an increase in levels of high-density lipoprotein (HDL), the so-called ‘good’ cholesterol.
The Revita DMR – duodenal mucosa resurfacing device, works by stripping away the lining of the duodenum, the first part of the digestive system after the stomach, which can become thickened by dietary fats, sugars and other foods in people with T2D.
This mucosal layer is responsible for producing the hormones that govern metabolism and this thickening reduces its efficiency. Rejuvenating the lining in this way improves blood sugar control, but more research is needed to find out how long this improvement continues or what the longer-term effect of the treatment might be.
To read our earlier coverage of this treatment, CLICK HERE.
